Two cases of severe hyperglycemia with injectable CAB/RPV-LA

HIV i-Base news story

Two cases of severe hyperglycemia have been reported several weeks after switching from stable oral ART to injectable long-acting cabotegravir/rilpivirine.

This is the first time this has been reported and the cases were published in the March 2026 issue of the journal Diabetes & Metabolism.

Both cases were men aged 60 and 62, with a history of hypertension but good CD4 counts on ART and viral load >30 copies/mL, who wanted to simplify treatment by switching.

Read the full news story here.